These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2532081)

  • 1. Human fibrinogen heterogeneity. A study of limited fibrinogen degradation.
    Regañón E; Vila V; Aznar J; Laiz B
    Clin Chim Acta; 1989 Sep; 184(1):7-17. PubMed ID: 2532081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercoagulable state after thrombolytic therapy in patients with acute myocardial infarction (AMI) treated with streptokinase.
    Vila V; Regañón E; Aznar J; Lacueva V; Ruano M; Laiz B
    Thromb Res; 1990 Mar; 57(5):783-94. PubMed ID: 2339369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of heparin on fibrinogen and D-dimer plasma levels in acute myocardial infarction treated with streptokinase.
    Salvioni A; Marenzi GC; Agostoni P; Grazi S; Guazzi MD
    Eur Heart J; 1994 May; 15(5):654-9. PubMed ID: 8056006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction.
    Prisco D; Bonechi F; Scarti L; Tramontana M; Abbate R; Gensini GF
    Angiology; 1990 Aug; 41(8):616-20. PubMed ID: 2117862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
    Salvioni A; Perego GB; Marenzi G; Lauri G; Giraldi F; Grazi S; Guazzi MD
    Eur Heart J; 1996 Feb; 17(2):230-6. PubMed ID: 8732376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial.
    Ostermann H; Schmitz-Huebner U; Windeler J; Bär F; Meyer J; van de Loo J
    Eur Heart J; 1992 Sep; 13(9):1225-32. PubMed ID: 1396833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial changes in coagulant activities after thrombolytic therapy for acute myocardial infarction.
    Goto S; Kawai Y; Abe S; Takahashi E; Handa S; Ogawa S; Watanabe K; Hori S; Ikeda Y
    Angiology; 1994 Apr; 45(4):273-81. PubMed ID: 8161005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The alpha(E)C domain of human fibrinogen-420 is a stable and early plasmin cleavage product.
    Applegate D; Steben LS; Hertzberg KM; Grieninger G
    Blood; 2000 Apr; 95(7):2297-303. PubMed ID: 10733499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction.
    Koster RW; Cohen AF; Hopkins GR; Beier H; Günzler WA; van der Wouw PA
    Thromb Haemost; 1994 Nov; 72(5):740-4. PubMed ID: 7534946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of DL and DH degradation products in the reactions of the plasmin hydrolysis of fibrinogen and fibrin].
    Rozenfel'd MA; Leonova VB; Khavkina LS
    Izv Akad Nauk SSSR Biol; 1991; (3):334-42. PubMed ID: 1835465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.
    Owen J; Friedman KD; Grossman BA; Wilkins C; Berke AD; Powers ER
    J Clin Invest; 1987 Jun; 79(6):1642-7. PubMed ID: 2953761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of the fibrinogen molecule and its phosphorylation state in myocardial infarction patients undergoing thrombolytic treatment.
    Haglund AC; Ronquist G; Frithz G; Ek P
    Thromb Res; 2000 Apr; 98(2):147-56. PubMed ID: 10713316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Coagulation studies and rheological measurements during streptokinase therapy of myocardial infarction (author's transl)].
    Theiss W; Volger E; Wirtzfeld A; Keisel I; Blömer H
    Klin Wochenschr; 1980 Jun; 58(12):607-15. PubMed ID: 6157050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.
    Francis CW; Connaghan DG; Marder VJ
    Circulation; 1986 Nov; 74(5):1027-36. PubMed ID: 3533310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procoagulant effects of thrombolytic therapy in acute myocardial infarction.
    Wang Y; Liu Q; Zhu J; Yuan Z; Ma X
    Chin Med Sci J; 2002 Mar; 17(1):36-9. PubMed ID: 12894883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombolytic therapy in acute myocardial infarction. A perspective.
    Sherry S
    Drugs; 1987; 33 Suppl 3():1-12. PubMed ID: 2960512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.
    Van de Werf F; Nobuhara M; Collen D
    Ann Intern Med; 1986 Mar; 104(3):345-8. PubMed ID: 3080936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role for fibrinogen in the streptokinase-dependent acquisition of plasmin(ogen) by group A streptococci.
    Wang H; Lottenberg R; Boyle MD
    J Infect Dis; 1995 Jan; 171(1):85-92. PubMed ID: 7798686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.